Active — Not RecruitingNot Applicable

Use of ctDNA for Monitoring of Stage III Colorectal Cancer

United States137 participantsStarted 2016-09

Plain-language summary

This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women with CRC Stage III A, B, or C * Age ≥18 years * Willingness to provide blood samples for research purposes * Ability to understand written informed consent document, and written informed consent provided Exclusion Criteria: * Blood sampling would compromise patients overall health such as presence of severe anemia * Unable to give informed consent

What they're measuring

ctDNA assessment and relation to clinical outcome

Timeframe: up to 5 years

Trial details

NCT IDNCT02842203

SponsorUniversity of Pittsburgh

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09

View on ClinicalTrials.gov More Stage III Colorectal Cancer trials